Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term bone and renal safety of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B
2014-004939-39Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Bone adverse events and clinically relevant BMD reduction through Week 96 and Percent change in bone mineral density from baseline through Week 96. Started Apr 2015; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2014-004939-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004939-39.